For the quarter ending 2025-09-30, BTAI made $98K in revenue. -$30,911K in net income. Net profit margin of -31541.84%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Product revenue, net | 98 | 120 | 168 | 289* |
| Cost of goods sold | 11 | 107 | 14 | 295* |
| Research and development | 8,740 | 10,256 | 4,554 | 10,735* |
| Selling, general and administrative | 5,381 | 5,609 | 5,699 | 8,793* |
| Restructuring costs | 194 | 0 | - | -1,172* |
| Total operating expenses | 14,326 | 15,972 | 10,267 | 18,650* |
| Loss from operations | -14,228 | -15,852 | -10,099 | -18,361* |
| Interest expense | 4,373 | 4,222 | 3,993 | 3,894* |
| Interest income | 236 | 230 | 279 | 672* |
| Other (income) expense, net | -12,546 | 657 | 6,559 | -5,091* |
| Net loss | -30,911 | -19,187 | -7,254 | -26,675 |
| Basic EPS | -2.18 | -2.45 | -1.5 | 0.355 |
| Diluted EPS | -2.18 | -2.45 | -1.5 | 0.355 |
| Basic Average Shares | 14,196,000 | 7,843,000 | 4,834,000 | -75,038,000 |
| Diluted Average Shares | 14,196,000 | 7,843,000 | 4,834,000 | -75,038,000 |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)